Doxorubicin-conjugated Polypeptide Nanoparticles Inhibit Metastasis in Two Murine Models of Carcinoma

Overview

Journal J Control Release

Specialty Pharmacology

Date 2015 Feb 1

PMID 25637704

Citations 20

Authors

Eric M Mastria

Mingnan Chen

Jonathan R McDaniel

Xinghai Li

Jinho Hyun

Mark W Dewhirst

Ashutosh Chilkoti

Affiliations

Soon will be listed here.

Abstract

Drug delivery vehicles are often assessed for their ability to control primary tumor growth, but the outcome of cancer treatment depends on controlling or inhibiting metastasis. Therefore, we studied the efficacy of our genetically encoded polypeptide nanoparticle for doxorubicin delivery (CP-Dox) in the syngeneic metastatic murine models 4T1 and Lewis lung carcinoma. We found that our nanoparticle formulation increased the half-life, maximum tolerated dose, and tumor accumulation of doxorubicin. When drug treatment was combined with primary tumor resection, greater than 60% of the mice were cured in both the 4T1 and Lewis lung carcinoma models compared to 20% treated with free drug. Mechanistic studies suggest that metastasis inhibition and survival increase were achieved by preventing the dissemination of viable tumor cells from the primary tumor.

Citing Articles

Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform.

Bidwell 3rd G Physiology (Bethesda). 2021; 36(6):367-381.

PMID: 34486397 PMC: 8560375. DOI: 10.1152/physiol.00026.2021.

Manganese Porphyrin and Radiotherapy Improves Local Tumor Response and Overall Survival in Orthotopic Murine Mammary Carcinoma Models.

Boss M, Oberley-Deegan R, Batinic-Haberle I, Talmon G, Somarelli J, Xu S Radiat Res. 2020; 195(2):128-139.

PMID: 33264413 PMC: 7962472. DOI: 10.1667/RADE-20-00109.1.

Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle-based Chemotherapy in -deleted Mouse Models of Sarcoma.

Dodd R, Scherer A, Huang W, McGivney G, Gutierrez W, Laverty E Clin Cancer Res. 2020; 26(18):5036-5047.

PMID: 32718998 PMC: 7641033. DOI: 10.1158/1078-0432.CCR-19-2597.

Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery.

Wang Z, Chen J, Little N, Lu J Acta Biomater. 2020; 111:20-28.

PMID: 32454086 PMC: 7245299. DOI: 10.1016/j.actbio.2020.05.026.

Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach.

Cheng Y, He C, Riviere J, Monteiro-Riviere N, Lin Z ACS Nano. 2020; 14(3):3075-3095.

PMID: 32078303 PMC: 7098057. DOI: 10.1021/acsnano.9b08142.

References

Meyer D, Chilkoti A . Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol. 1999; 17(11):1112-5. DOI: 10.1038/15100. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Yang Y, Pan D, Luo K, Li L, Gu Z . Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Biomaterials. 2013; 34(33):8430-43. DOI: 10.1016/j.biomaterials.2013.07.037. View

Lammers T, Kiessling F, Hennink W, Storm G . Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2011; 161(2):175-87. DOI: 10.1016/j.jconrel.2011.09.063. View

Jia Y, Yuan M, Yuan H, Huang X, Sui X, Cui X . Co-encapsulation of magnetic Fe3O4 nanoparticles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int J Nanomedicine. 2012; 7:1697-708. PMC: 3356178. DOI: 10.2147/IJN.S28629. View

McDaniel J, MacEwan S, Dewhirst M, Chilkoti A . Doxorubicin-conjugated chimeric polypeptide nanoparticles that respond to mild hyperthermia. J Control Release. 2012; 159(3):362-7. PMC: 3348377. DOI: 10.1016/j.jconrel.2012.02.030. View

Kamaly N, Xiao Z, Valencia P, Radovic-Moreno A, Farokhzad O . Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012; 41(7):2971-3010. PMC: 3684255. DOI: 10.1039/c2cs15344k. View

Schroeder A, Heller D, Winslow M, Dahlman J, Pratt G, Langer R . Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2011; 12(1):39-50. DOI: 10.1038/nrc3180. View

Gao Z, Tian L, Hu J, Park I, Bae Y . Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J Control Release. 2011; 152(1):84-9. PMC: 3107897. DOI: 10.1016/j.jconrel.2011.01.021. View

10.

MacKay J, Chen M, McDaniel J, Liu W, Simnick A, Chilkoti A . Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater. 2009; 8(12):993-9. PMC: 2862348. DOI: 10.1038/nmat2569. View

11.

Joyce J, Pollard J . Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9(4):239-52. PMC: 3251309. DOI: 10.1038/nrc2618. View

12.

Davis M, Chen Z, Shin D . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-82. DOI: 10.1038/nrd2614. View

13.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

14.

Pulaski B, Ostrand-Rosenberg S . Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2008; Chapter 20:Unit 20.2. DOI: 10.1002/0471142735.im2002s39. View

15.

Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G . Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol. 2007; 18(7):1159-64. DOI: 10.1093/annonc/mdl477. View

16.

Brusa P, Immordino M, Rocco F, Cattel L . Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. Anticancer Res. 2007; 27(1A):195-9. View

17.

Duncan R . Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006; 6(9):688-701. DOI: 10.1038/nrc1958. View

18.

Mehlen P, Puisieux A . Metastasis: a question of life or death. Nat Rev Cancer. 2006; 6(6):449-58. DOI: 10.1038/nrc1886. View

19.

Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M . Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo. Int Immunopharmacol. 2005; 5(2):281-8. DOI: 10.1016/j.intimp.2004.09.032. View

20.

Kuerer H, Newman L, Smith T, Ames F, Hunt K, Dhingra K . Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2):460-9. DOI: 10.1200/JCO.1999.17.2.460. View